BOSTON, July 17,
2024 /PRNewswire/ -- Immunocan announced the
successful construction of new strain of fully human antibody
platform: ImmuMab® HKL mouse. This new mouse was created by in-situ
replacing the variable region of Immunoglobulin genes of mouse by
its counterparts from human. With Lambda light chain genes
humanized, ImmuMab® HKL mouse now contains approximately 3.2 Mb of
human immunoglobulin variable region genes, making it the humanized
mouse with the longest human immunoglobulin variable regions in the
world.
Since the first mouse-derived monoclonal antibody drug OKT3
(muromonab-CD3) was marketed in 1986, over 120 antibody drugs from
different sources have been approved by FDA and brought clinical
benefits to patients. Despite flexibility and well-established
application process, ritual use of mice during antibody generation
brought limitations for drug development space. Due to the low
utilization of Immunoglobulin Lambda genes in wildtype mice (about
5%, varying by strain), antibodies with Lambda light chain
(λ-antibodies) have always been under-scrutinized. As of
December 31, 2023, only 14
FDA-approved antibody drugs contain Lambda light chain, and most of
these are from transgenic mice or human antibody library used in
display technologies.
In humans, naturally occurring λ-antibodies are approximately
35% of the antibody repertoire and plays important role in adaptive
immunity. Different individuals generate immune repertoires with
different preferences of light chain type in response to different
immunogens. Within the immune repertoire against the same antigen,
λ-antibodies can target different epitopes from κ-antibodies.
Therefore, using an antibody generation model containing human
Lambda light chains can significantly enhance the epitope coverage
of the immune repertoire and increase the success rate of obtaining
candidate antibodies fitting target product profile.
By proprietary Massive-fragment Across Species In-situ
Replacement Technology (MASIRT®), Immunocan achieved humanization
of Lambda light chain variable regions of ImmuMab® mouse, which
increased the total humanized immunoglobulin variable region to 3.2
Mb. This innovation provides the industry with source of λ-antibody
repertoires of higher diversity and developability compared to
existing platforms.
For most antigens, especially in the early stage of discovery
programs, the light chain preference of preferred lead antibodies
is unpredictable. Using mouse generating a significant quantity of
human λ-antibodies can prevent the early exclusion of superior lead
molecules during antibody generation, increasing the probability of
drug development success.
In addition to ImmuMab® HKL mouse, Immunocan has already
constructed platforms including ImmuMab® HK mouse generating fully
human antibody (κ-antibodies), ImmuMab Heavy® mouse generating
fully human heavy-chain-only antibody (HCAb), ImmuAlpaca® mouse
generating alpaca-derived antibody, and ImmuMab Light® mouse
generating fully human common-light-chain antibody. ImmuHeavy®
Rabbit is currently under construction to generate rabbit
heavy-chain-only antibodies. By continuously innovating in-vivo
antibody discovery platforms, Immunocan aims to help partners
accelerate the development of novel therapeutics.
Immunocan's multi-species antibody generation strategy not only
expands the potential for antibody discovery and development but
also provides more therapeutic options for treating complex
diseases. Immunocan is looking forward to introducing its
innovative antibody discovery platforms to global research partners
and seek collaboration to bring safer and more effective
therapeutic products to patients worldwide.
About the Massive-fragment Across Species In-situ Replacement
Technology (MASIRT®)
Immunocan's core technology features one-step gene replacement
at Mb scale between two species. Its advantageous
genome-engineering efficiency enables rapid construction of
multiple specialized antibody discovery platforms, including mice
generating fully human antibodies or alpaca antibodies and rabbits
generating fully human antibodies (under construction).
About Immunocan
Immunocan was founded in 2020 and specializes in using gene
editing technology to replace immunoglobulin variable region genes
in various animals, resulting in genetically engineered animals
capable of producing fully human antibodies and other innovative
modalities. The company is committed to offering cutting-edge
antibody discovery platforms to worldwide drug research partners,
with the goal of developing safer and more effective treatments for
human diseases.
For more information, please visit:
https://immunocan.com/
For business cooperation, please contact:
BD@immunocan.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/increasing-possibility-of-success-by-expanded-antibody-repertoires-with-lambda-light-chain--immunocan-launches-new-mouse-strain-of-fully-human-antibody-platform-immumab-hkl-mouse-302199446.html
SOURCE Immunocan